{
    "id": "35b5b442-c8e2-48fc-e063-6294a90a23f0",
    "indications": {
        "text": "baclofen tablets , usp useful alleviation signs symptoms spasticity resulting multiple sclerosis , particularly relief flexor spasms concomitant pain , clonus , muscular rigidity . patients reversible spasticity baclofen treatment aid restoring residual function . baclofen tablets , usp may also value patients spinal cord injuries spinal cord diseases . baclofen tablets , usp indicated treatment skeletal muscle spasm resulting rheumatic disorders . efficacy baclofen stroke , cerebral palsy , parkinson 's disease established , therefore , recommended conditions .",
        "doid_entities": [
            {
                "text": "multiple sclerosis (DOID:2377)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2377"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "cerebral palsy (DOID:1969)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1969"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "determination optimal requires individual titration . start therapy low increase gradually optimum effect achieved ( usually 40-80 mg daily ) . following titration schedule suggested : 5 mg t.i.d . 3 days 10 mg t.i.d . 3 days 15 mg t.i.d . 3 days 20 mg t.i.d . 3 days thereafter additional increases may necessary total daily dose exceed maximum 80 mg daily ( 20 mg q.i.d . ) . lowest dose compatible optimal response recommended . benefits evident reasonable trial period , patients slowly withdrawn ( , abrupt withdrawal ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "baclofen tablets , usp 5 mg available white white , round flat-faced , beveled edge tablets debossed `` 023 `` one side plain side , containing 5 mg baclofen usp packaged bottles 100 tablets . ndc 76420-356-30 30s count ( repackaged ndc 52817-319-xx ) ndc 76420-356-60 60s count ( repackaged ndc 52817-319-xx ) ndc 76420-356-90 90s count ( repackaged ndc 52817-319-xx ) ndc 76420-356-01 100s count ( relabeled ndc 52817-319-10 ) baclofen tablets , usp 10 mg available white white , round flat-faced , beveled edge tablets debossed `` 024 `` one side score side , containing 10 mg baclofen usp packaged bottles 100 , 500 1000 tablets . ndc 76420-357-30 30s count ( repackaged ndc 52817-320-xx ) ndc 76420-357-60 60s count ( repackaged ndc 52817-320-xx ) ndc 76420-357-90 90s count ( repackaged ndc 52817-320-xx ) ndc 76420-357-01 100s count ( relabeled ndc 52817-320-10 ) ndc 76420-357-05 500s count ( relabeled ndc 52817-320-50 ) ndc 76420-357-00 1000s count ( relabeled ndc 52817-320-00 ) baclofen tablets , usp 15 mg available white white , round flat-faced , beveled edges tablets debossed `` \u03bbb1 `` one side plain side , containing 15 mg baclofen usp packaged bottles 100 tablets . ndc 76420-358-30 30s count ( repackaged ndc 52817-318-xx ) ndc 76420-358-60 60s count ( repackaged ndc 52817-318-xx ) ndc 76420-358-90 90s count ( repackaged ndc 52817-318-xx ) ndc 76420-358-01 100s count ( relabeled ndc 52817-318-10 ) baclofen tablets , usp 20 mg available white white , round flat-faced , beveled edge tablets debossed `` 025 `` one side score side , containing 20 mg baclofen usp packaged bottles 100 , 500 1000 tablets . ndc 76420-359-30 30s count ( repackaged ndc 52817-321-xx ) ndc 76420-359-60 60s count ( repackaged ndc 52817-321-xx ) ndc 76420-359-90 90s count ( repackaged ndc 52817-321-xx ) ndc 76420-359-01 100s count ( relabeled ndc 52817-321-10 ) ndc 76420-359-05 500s count ( relabeled ndc 52817-321-50 ) ndc 76420-359-00 1000s count ( relabeled ndc 52817-321-00 ) pharmacist : dispense well closed container defined usp , child-resistant closure ( required ) . store 20\u00b0 25\u00b0c ( 68\u00b0to 77\u00b0f ) [ usp controlled room temperature ] . keep medications reach children . relabeled repackaged : enovachem pharmaceuticals torrance , ca 90501",
    "adverseReactions": "hypersensitivity baclofen .",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "BACLOFEN",
            "code": "H789N3FKE8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2972"
        }
    ],
    "organization": "Asclemed USA, Inc.",
    "name": "BACLOFEN",
    "effectiveTime": "20250522",
    "indications_original": "Baclofen tablets, USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.\n                  Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets, USP may also be of some value in patients with spinal cord injuries and other spinal cord diseases.\n                  Baclofen tablets, USP are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.\n                  The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions.",
    "contraindications_original": "The determination of optimal dosage requires individual titration. Start therapy at a low dosage and increase gradually until optimum effect is achieved (usually between 40-80 mg daily).\n                  \n                  The following dosage titration schedule is suggested:\n                  5 mg t.i.d. for 3 days\n                  10 mg t.i.d. for 3 days\n                  15 mg t.i.d. for 3 days\n                  20 mg t.i.d. for 3 days\n                  Thereafter additional increases may be necessary but the total daily dose should not exceed a maximum of 80 mg daily (20 mg q.i.d.).\n                  The lowest dose compatible with an optimal response is recommended. If benefits are not evident after a reasonable trial period, patients should be slowly withdrawn from the drug (See\n \n  \n                        WARNINGS\n                     ,\n \n  Abrupt Drug Withdrawal).",
    "warningsAndPrecautions_original": "Baclofen Tablets, USP 5 mg are available as a White to off white, round flat-faced, beveled edge tablets debossed with \"023\" on one side and plain on other side, containing 5 mg baclofen USP packaged in bottles of 100 tablets.\n                  \n                  NDC 76420-356-30\u00a0\u00a0 30s count (repackaged from NDC 52817-319-XX)\n                  NDC 76420-356-60\u00a0\u00a0 60s count (repackaged from NDC 52817-319-XX)\n                  NDC 76420-356-90\u00a0\u00a0 90s count (repackaged from NDC 52817-319-XX)\n                  NDC 76420-356-01 \u00a0 100s count (relabeled from NDC 52817-319-10)\n                  \n                  Baclofen Tablets, USP 10 mg are available as a White to off white, round flat-faced, beveled edge tablets debossed with \"024\" on one side and score on other side, containing 10 mg baclofen USP packaged in bottles of 100, 500 and 1000 tablets.\n                  \n                  NDC 76420-357-30 30s count (repackaged from NDC 52817-320-XX)\n                  NDC 76420-357-60 60s count (repackaged from NDC 52817-320-XX)\n                  NDC 76420-357-90 90s count (repackaged from NDC 52817-320-XX)\n                  NDC 76420-357-01 100s count (relabeled from NDC 52817-320-10)\n                  NDC 76420-357-05 500s count (relabeled from NDC 52817-320-50)\n                  NDC 76420-357-00 1000s count (relabeled from NDC 52817-320-00)\n                  \n                  Baclofen Tablets, USP 15 mg are available as a White to off white, round flat-faced, beveled edges tablets debossed with \"\u039bB1\" on one side and plain on the other side, containing 15 mg baclofen USP packaged in bottles of 100 tablets.\n                  \n                  NDC 76420-358-30 30s count (repackaged from NDC 52817-318-XX)\n                  NDC 76420-358-60 60s count (repackaged from NDC 52817-318-XX)\n                  NDC 76420-358-90 90s count (repackaged from NDC 52817-318-XX)\n                  NDC 76420-358-01 100s count (relabeled from NDC 52817-318-10)\n                  \n                  Baclofen Tablets, USP 20 mg are available as a White to off white, round flat-faced, beveled edge tablets debossed with \"025\" on one side and score on other side, containing 20 mg baclofen USP packaged in bottles of 100, 500 and 1000 tablets.\n                  \n                  NDC 76420-359-30 30s count (repackaged from NDC 52817-321-XX)\n                  NDC 76420-359-60 60s count (repackaged from NDC 52817-321-XX)\n                  NDC 76420-359-90 90s count (repackaged from NDC 52817-321-XX)\n                  NDC 76420-359-01 100s count (relabeled from NDC 52817-321-10)\n                  NDC 76420-359-05 500s count (relabeled from NDC 52817-321-50)\n                  NDC 76420-359-00 1000s count (relabeled from NDC 52817-321-00)\n                  \n                  PHARMACIST: Dispense in a well closed container as defined in the USP, with a child-resistant closure (as required).\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0to 77\u00b0F) [See USP Controlled Room Temperature].\n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.\n                  \n                     Relabeled and Repackaged by:\n                  \n                  Enovachem PHARMACEUTICALS\n                  Torrance, CA 90501",
    "adverseReactions_original": "Hypersensitivity to baclofen.",
    "drug": [
        {
            "name": "BACLOFEN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2972"
        }
    ]
}